Idiopathic Pulmonary Fibrosis, Systemic Sclerosis-Associated Interstitial Lung Disease research hub

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

This study is testing a new medicine, Vixarelimab, for two serious lung conditions: Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. It aims to see if the medicine can improve lung function and safety compared to a dummy treatment.